PEPTIDE BASED TARGETED RADIONUCLIDE THERAPIES; SCIENCE BEHIND THE SUCCESS.

Abstract

The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide therapies have been in use since 1945. In the past 20 years, due to advancement in the nanotechnology and targeting cell receptors; radionuclide therapies have emerged as a subspecialty in nuclear medicine. Through this article, we would like to briefly describe the evolution of peptide-based radionuclide therapies, with a little emphasis on their clinical applications. Key words: Peptide-based radiopharmaceuticals, radionuclide therapy, somatostatin-receptor-positive neuroendocrine tumour